
The Alfa Medical Group is a leading health care company in Egypt. Now, UK development finance institution CDC invests alongside the Simon Rowlands single family office (Africa Platform Capital) in a $100M minority equity investment.Alfa Medical
Group: Leading Egyptian diagnostics companyThe Egyptian Alfa Medical Group consists of three main parts: the two diagnostics companies Alfa Scan and Alfa Laboratories as well as the El-Safa Hospital. The company runs more than 140 medical labs and six radiology centers. The El Safa hospital hosts 170 beds. Furthermore, the construction of two more hospitals is ongoing. Through the investments, the Alfa group mainly wants to expand its lab business, especially in underserved Egyptian regions.Impact investment by UK-based Rowlands single family officeThe $100M investment of CDC represents the largest impact investment of the institution. Through the investment, the healthcare quality in Egypt is further improved. Along with CDC, Africa Platform Capital is investing in Alfa Medical. Africa Platform Capital is the single family office of Simon Rowlands, who is an expert in healthcare and co-founder of leading private equity firm Cinven. The invests mainly in private equity deals in the consumer and healthcare sector in sub-Saharan Africa.
Source: Picture source: You might like these family office articlesRelevant family office lists Rated 5.00 out of 5 Deal €649,99 Original price was: €649,99.€499,99Current price is: €499,99. including VAT Rated 5.00 out of 5 €799,99 including VAT Rated 4.67 out of 5 €1.499,99 including VAT Rated 4.67 out of 5 €399,99 including VAT
User Comments1. D.
Johnson: Comment sample 1...2. Olivia E.: Comment sample 2...3. C.
Miller: Comment sample 3...4. M.
Collins: Comment sample 4...5. Ethan
Mitchell: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.

(Editors: admin)
Disclaimer & Copyright Notice:
This article is edited and compiled by the editorial team at WealthShield Asia based on publicly available information. It is intended for informational purposes only and does not constitute legal, financial, or investment advice.
We respect intellectual property rights. If you believe that any part of this article infringes upon your copyright or other legal rights, please contact us at
admin@wealthshield.asia. We will promptly review and remove the content if necessary.
All rights reserved. Unauthorized reproduction or redistribution is prohibited.